Server:nginx/1.4.6 (Ubuntu)...
The main IP address: 178.62.74.55,Your server United Kingdom,London ISP:DigitalOcean London TLD:com CountryCode:GB
The description :© 2018 copyright privacy policy designed and built by onespacemedia home the company r & d pipeline leadership team history partnering news events contact discovering innovative cancer therapies f...
This report updates in 18-Jul-2018
Created Date: | 2005-02-10 |
Changed Date: | 2017-02-11 |
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host sentineloncology.com. Currently, hosted in United Kingdom and its service provider is DigitalOcean London .
Latitude: | 51.508529663086 |
Longitude: | -0.12574000656605 |
Country: | United Kingdom (GB) |
City: | London |
Region: | England |
ISP: | DigitalOcean London |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx/1.4.6 (Ubuntu) containing the details of what the browser wants and will accept back from the web server.
Content-Encoding: | gzip |
Transfer-Encoding: | chunked |
Vary: | Accept-Encoding |
Server: | nginx/1.4.6 (Ubuntu) |
Connection: | keep-alive |
Date: | Tue, 17 Jul 2018 23:14:59 GMT |
X-Frame-Options: | SAMEORIGIN |
Content-Type: | text/html; charset=utf-8 |
soa: | ns1045.ui-dns.de. hostmaster.1and1.co.uk. 2015081701 28800 7200 604800 600 |
txt: | "v=spf1 include:spf.protection.outlook.com -all" |
ns: | ns1045.ui-dns.org. ns1045.ui-dns.com. ns1045.ui-dns.biz. ns1045.ui-dns.de. |
ipv4: | IP:178.62.74.55 ASN:14061 OWNER:DIGITALOCEAN-ASN - DigitalOcean, LLC, US Country:EU |
mx: | MX preference = 1, mail exchanger = sentineloncology-com.mail.eo.outlook.com. |
© 2018 copyright privacy policy designed and built by onespacemedia home the company r & d pipeline leadership team history partnering news events contact discovering innovative cancer therapies from initial concept to the delivery of candidate drugs - we're a drug discovery company specialising in cutting-edge treatments for diseases with an unmet need learn about us more than 10 years of experience in advancing novel concepts to candidate drug selection our track record of excellence means that we partner with some of the world's most innovative and established biotechnology and pharmaceutical companies. learn more about partnering an extensive pipeline of r&d programmes from concept to the delivery of candidate drugs, is developing a portfolio of new therapies and is committed to improving the treatment options for patients view our pipeline our upcoming events aacr-nci-eortc 26th - 30th oct. 2017 philadelphia view event bio europe 6th - 9th nov. 2017 berlin view event bio international convention 4th - 7th june 2018 boston view event more events our latest news receives innovate uk grant to develop new drugs for the treatment of glioblastoma multiforme read article receive innovate uk grant to study feasibility of drug in the treatment of alzheimer's disease read article more news "it's our vision to develop oncology drugs that are devoid of the systemic toxicities often associated with chemotherapeutics" bob boyle, chief executive officer & founder meet the team & board
http://www.sentineloncology.com/partnering
http://www.sentineloncology.com/team
http://www.sentineloncology.com/team/
http://www.sentineloncology.com/partnering/
http://www.sentineloncology.com/pipeline/
http://www.sentineloncology.com/company/
http://www.sentineloncology.com/#cd-nav
http://www.sentineloncology.com/pipeline
http://www.sentineloncology.com/company
http://www.sentineloncology.com/news/
http://www.sentineloncology.com/news/2018/may/1/sol_iuk_gbm/
http://www.sentineloncology.com/events/
http://www.sentineloncology.com/contact/
http://www.sentineloncology.com/news/2017/aug/1/sentinel-oncology-receive-innovate-uk-grant-study-/
http://www.sentineloncology.com/history/
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Domain Name: SENTINELONCOLOGY.COM
Registry Domain ID: 142157703_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.1and1.com
Registrar URL: http://registrar.1and1.info
Updated Date: 2017-02-11T08:27:23Z
Creation Date: 2005-02-10T17:54:49Z
Registry Expiry Date: 2018-02-10T17:54:49Z
Registrar: 1&1 Internet SE
Registrar IANA ID: 83
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.6105601459
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS33.1AND1.CO.UK
Name Server: NS34.1AND1.CO.UK
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-12-23T02:56:55Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR 1&1 Internet SE
SERVERS
SERVER com.whois-servers.net
ARGS domain =sentineloncology.com
PORT 43
TYPE domain
DOMAIN
NAME sentineloncology.com
CHANGED 2017-02-11
CREATED 2005-02-10
STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
NSERVER
NS33.1AND1.CO.UK 217.160.80.150
NS34.1AND1.CO.UK 217.160.81.150
REGISTERED yes
The following list shows you to spelling mistakes possible of the internet users for the website searched .